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Invasive aspergillosis (IA) is a life-threatening fungal disease commonly diagnosed
among individuals with immunological deficits, namely hematological patients undergoing
chemotherapy or allogeneic hematopoietic stem cell transplantation. Vaccines are not
available, and despite the improved diagnosis and antifungal therapy, the treatment of
IA is associated with a poor outcome. Importantly, the risk of infection and its clinical
outcome vary significantly even among patients with similar predisposing clinical factors
and microbiological exposure. Recent insights into antifungal immunity have further
highlighted the complexity of host-fungus interactions and the multiple pathogen-sensing
systems activated to control infection. How to decode this information into clinical
practice remains however, a challenging issue in medical mycology. Here, we address
recent advances in our understanding of the host-fungus interaction and discuss the
application of this knowledge in potential strategies with the aim of moving toward
personalized diagnostics and treatment (theranostics) in immunocompromised patients.
Ultimately, the integration of individual traits into a clinically applicable process to predict
the risk and progression of disease, and the efficacy of antifungal prophylaxis and therapy,
holds the promise of a pioneering innovation benefiting patients at risk of IA.
Keywords: invasive aspergillosis, stem cell transplantation, antifungal immunity, single nucleotide polymorphism,
personalized medicine
Introduction
Aspergillosis includes an extensive spectrum of diseases caused by fungi of the genus Aspergillus
with clinical manifestations that range from colonization to allergic bronchopulmonary aspergillosis
and disseminated forms of infection (Segal, 2009). The prevalence of invasive aspergillosis (IA) has
steadily increased in the last decades, mostly due to the advent of solid organ and hematopoietic
stem cell transplantation (HSCT), and the increased use of chemotherapy and immunosuppression
(Kontoyiannis et al., 2010; Pagano et al., 2010). Although the diagnosis of IA has improved,
namely because of the introduction of biomarkers such as the detection of galactomannan in the
clinical practice (Morrissey et al., 2013), successful treatment is still a challenging endeavor. Indeed,
established infection is difficult to eradicate, resulting in associated mortality rates ranging from 40
to 90% (Walsh et al., 2008).
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The extensive use of empiric antifungal therapy is a major
concern given the potential development of resistance in the
pathogen. The emergence of azole-resistant strains of Aspergillus
fumigatus (Steinmann et al., 2015) underscores the need for per-
sonalized diagnostic and risk prediction approaches based on
individual traits that may allow targeting antifungal therapy and
improving outcomes without unnecessary empiric therapy. Sev-
eral host genetic variants have been proposed as suitable markers
to categorize patients with the highest risk of infection (Cunha
et al., 2013). However, many challenges confront the develop-
ment of these predictive tools. Among them, our insufficient
understanding of the critical immune defects that predispose to
the infection and the lack of validation of genetic diagnostics in
well-designed clinical trials.
The purpose of this review is to reposition novel findings on the
host-fungus interaction and to discuss the challenges in exploiting
this knowledge to the design of patient-tailored diagnostic or
therapeutic approaches to deliver to specific target populations.
The Host-fungus Interaction: What’s New?
The physical barriers afforded by the respiratory mucosa confer
the first line of innate resistance to fungal infection. Because
of their small size, conidia may reach the lung alveoli, where
they are phagocytosed and killed through the production of
reactive oxygen species (ROS) by resident macrophages, whereas
neutrophils are instead proficient at handling hyphae germinat-
ing from conidia that escape macrophage surveillance through
an array of extracellular killing mechanisms (Ibrahim-Granet
et al., 2003; Cunha et al., 2014b; Heinekamp et al., 2015).
This morphotype preference may be in part due to the abil-
ity of neutrophils to sense microbe size and selectively release
neutrophil extracellular traps in response to larger structures
(Branzk et al., 2014). Importantly, recent findings also suggest
that lung epithelial cells act as an active extension of the innate
immune system, operating as a surveillance mechanism sens-
ing fungal spores and prompting antifungal effector responses
(Osherov, 2012).
Innate immune cells are equipped with pattern recogni-
tion receptors (PRRs) able to discriminate pathogen-associated
molecular patterns (PAMPs; Bourgeois and Kuchler, 2012; Plato
et al., 2015). Stimulation of antigen-presenting cells, including
macrophages and dendritic cells (DCs), leads to the activation
and recruitment of lymphocytes, and the development of adaptive
antifungal immune responses. Once committed, T cells monitor
the host for infection and mobilize appropriate effector functions
by inducing cytokines and cytolytic molecules, which are instru-
mental in rallying and activating professional phagocytes to the
site of microbial deposition, thus providing a prompt and effective
control of infection (Romani, 2011).
The fungal cell wall is the main source of PAMPs owing to
its dynamic composition and structural properties according to
morphotype, growth stage and environmental conditions (Latge,
2010). Toll-like receptor (TLR)-2 (in cooperation with TLR1 and
TLR6), TLR3, TLR4, and TLR9, and the C-type lectin receptors
dectin-1, dendritic cell-specific intercellular adhesion molecule
3 grabbing non-integrin (DC-SIGN) and mannose receptor are
the most important PRRs recognizing fungal PAMPs including
mannan, b-glucan and nucleic acids (Romani, 2011).
The Host Perspective
The immune response to A. fumigatus is determined not only
by the relative degree of stimulation of the individual PRRs but
also by the level of receptor cooperation and cellular localization.
Indeed, a sequential activation of distinct signal transduction
pathways through the PRR adapters myeloid differentiation pri-
mary response 88 (MyD88) and caspase-associated recruitment
domain 9 (CARD9) in the respiratory epithelium and hematopoi-
etic compartment in response to infection was recently reported
(Jhingran et al., 2015). By means of a partial overlap, these signals
ensure optimal chemokine induction, neutrophil recruitment, and
fungal clearance within the respiratory tract.
Patients undergoing immunosuppressive regimens based on
calcineurin inhibitors such as cyclosporine A or corticosteroids
are highly susceptible to disseminated fungal infections. Previous
work demonstrated that calcineurin is an important regulator
of dectin-1-mediated signaling and activation of immunity to
Candida albicans (Greenblatt et al., 2010), and that corticosteroid
immunosuppression blocks dectin-1-mediated signaling required
for maturation of A. fumigatus phagosomes (Kyrmizi et al., 2013).
More recently, the calcineurin inhibitor tacrolimus was found to
impair primary alveolar macrophage activation in response to A.
fumigatus by preventing a signaling pathway involving a TLR9-
Bruton’s tyrosine kinase-calcineurin-nuclear factor of activated
T-cells axis required for proinflammatory cytokine production
(Herbst et al., 2015). Taken together, these findings suggest that
disseminated fungal infections seen in these patients are not
just a general consequence of systemic suppression of adaptive
immunity but are, rather, a result of the specific blockade of
evolutionarily conserved innate pathways for fungal resistance.
Another important feature of dectin-1-mediated signaling in
response to A. fumigatus is the activation of the nucleotide-
binding oligomerization domain-like receptor family, pyrin
domain containing 3 (NLRP3) inflammasome leading to the pro-
duction of bioactive interleukin (IL)-1b (Said-Sadier et al., 2010).
Indeed, members of the IL-1 receptor family of cytokines are
critical effector molecules in antifungal immunity (Gresnigt and
van de Veerdonk, 2014). By preventing activation of the NLRP3
inflammasome and reducing IL-1b secretion, IL-37 was recently
found to act as a broad spectrum inhibitor of innate responses
to fungal infection-mediated inflammation (Moretti et al., 2014).
Along this line, the increased IL-1b release intrinsically associ-
ated to chronic granulomatous disease (CGD) was found to be
reverted by the use of IL-1 receptor antagonist (IL-1Ra), leading
to restrained neutrophil recruitment and T helper 17 responses,
thereby protecting from IA (de Luca et al., 2014).
Soluble PRRs found in the fluids lining the epithelial surfaces
support fungal sensing by binding to conidia and enhancing their
uptake by phagocytes. Among these, the long pentraxin 3 (PTX3)
was demonstrated to play a non-redundant role in antifungal
host defense (Garlanda et al., 2002) by enhancing recognition and
phagocytosis through mechanisms that depend on Fcg receptor,
CD11b and complement activation (Moalli et al., 2010). Engage-
ment of myeloid differentiation protein 2 (MD-2) during uptake
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of PTX3-opsonized conidiawas also revealed to activate TLR4 sig-
naling converging on the production of type I interferons (Bozza
et al., 2014). This suggests that in addition to pro-phagocytic
properties, PTX3 is able to elicit antifungal effector mechanisms
associated with limited immunopathology, thereby highlighting
potential mechanisms of action underlying its favorable syner-
gism with antifungal therapy against IA (Lo Giudice et al., 2012;
Marra et al., 2014).
The Pathogen Perspective
Fungi have evolved their own elaborate mechanisms to escape
innate immunity. By masking dectin-1 and dectin-2-dependent
recognition, the hydrophobin layer of A. fumigatus conidia
restrains neutrophil infiltration and cytokine production (Aima-
nianda et al., 2009; Carrion Sde et al., 2013). Galactosamino-
galactan (GAG), a polysaccharide of the fungal cell wall pro-
duced by glucose epimerases (Lee et al., 2014), also hampers
neutrophil recruitment (Fontaine et al., 2011). GAG functions as
an adhesin, mediating adherence and suppressing host inflamma-
tory responses, in part through masking cell wall b-glucan from
recognition by dectin-1 (Gravelat et al., 2013). The immunosup-
pressive properties of GAG have also been attributed to its potent
ability to induce IL-1Ra (Gresnigt et al., 2014), a finding further
highlighting a possible therapeutic option targeting IL-1Ra in IA.
Genomic and transcriptomic approaches have revealed that
fungal pathogenicity depends also onmechanisms regulating fun-
gal metabolism and response to stress in adaptation to the host
environment. In particular, the ability of A. fumigatus to adapt to
hypoxic microenvironments has been found to involve the pro-
duction of secondary metabolites that promote lung inflamma-
tion, exacerbate infection and influence subsequent host immune
responses (Grahl et al., 2011). Given the need of myeloid cells to
adapt to hypoxic and inflamed microenvironments that develop
during infection, the hypoxia-inducible factor 1-alpha (HIF-1a)
has been found to be essentially required for chemokine pro-
duction and maintenance of neutrophil numbers in the lungs of
infected animals (Shepardson et al., 2014).
Effector T cell responses are also targeted by fungi. For example,
mucosal vaccination was found to subvert T cell priming by
impairing chemokine signals on egress of inflammatory mono-
cytes from the bone marrow and their recruitment to the lung
(Wuthrich et al., 2012). This finding is even more significant con-
sidering the role of inflammatorymonocytes in orchestrating anti-
fungal immunity in the lung by regulating the conidiocidal activity
of neutrophils and their own differentiation to DCs (Espinosa
et al., 2014). Importantly, inflammatory monocytes are required
for optimal IL-1a expression in the lungs, which in turn regulates
the early accumulation of neutrophils in the lung (Caffrey et al.,
2015).
Host Genetic Determinants of Risk of IA
The inborndeficiency of the phagocyte nicotinamide adenine din-
ucleotide phosphate (NADPH) oxidase leading to a defective pro-
duction of ROS and underlying CGD is the best known example
of primary immunodeficiency associated with a distinctive pre-
disposition to IA (Vinh, 2011). Patients with autosomal-dominant
hyper-IgE syndrome (AD-HIES) are also at risk for IA (Vinh et al.,
2010); however, the susceptibility of AD-HIES patients classically
results from concurrent anatomical lung defects from previous
bacterial infections and defective STAT3-dependent epithelial
immunity (Holland et al., 2007). For most individuals however,
the genetic propensity to IA has a polygenic source that acts in
combination with other remarkable predisposing variants (e.g.,
the profound immunosuppression typical of many clinical set-
tings), and thatmay translate into further immunological dysfunc-
tion, ultimately increasing the proneness to infection.
Our increasing ability to analyze human variability at the DNA
level has made possible the identification of genetic factors impli-
cated in the development of IA in hematological patients (Cunha
et al., 2013), providing important insights into the mechanisms
of human diversity underlying increased susceptibility to IA.
Although genetic profiling is nowadays regarded as a promising
methodology to exploit in the future toward improved diagnosis
and therapy of fungal diseases (Cunha and Carvalho, 2012), this
field is still bedeviled by difficulties, mostly related to hetero-
geneity of cohorts, sample size, selection bias, and statistical flaws
(van der Velden et al., 2011), which compromise the clinical
applicability of this knowledge.
The identification of a donor haplotype in TLR4 increasing risk
of IA after HSCT was one of the first solid reports illustrating
the remarkable influence of host genetics on the susceptibility to
IA (Bochud et al., 2008). This phenotype was associated with a
delayed T cell and natural killer T cell immune reconstitution
after transplant (Koldehoff et al., 2013). However, despite TLR4
polymorphisms have also been linked with chronic aspergillosis
in immunocompetent individuals (Carvalho et al., 2008) and
fungal colonization in HSCT recipients (Carvalho et al., 2009),
their prognostic significance remains unclear, since the exact
mechanism(s) through which TLR4 deficiency impacts human
antifungal immunity remain to be identified. Along this line, the
early finding that genetic variants in TLR1 and TLR6 predisposed
to IA among HSCT recipients (Kesh et al., 2005) was recently
supported by evidence demonstrating the defective production of
crucial antifungal cytokines and chemokines by TLR1- and TLR6-
deficient mouse cells after stimulation with A. fumigatus (Rubino
et al., 2012).
The discovery that sensing of fungal RNA by TLR3 was
required for the activation of protective memory CD8+ T cells
responses in experimental aspergillosis was complemented by the
identification of a regulatory variant impairing the expression of
the human receptor in human DCs and hampering the efficient
priming of memory CD8+ responses (Carvalho et al., 2012b).
These findings suggest that, by interpreting immunogenetic sig-
natures and identifying subtle differences in immune profiles,
response efficiencies to potential antifungal vaccination strategies
are likely to be discriminated. In fact, themeasurement ofA. fumi-
gatus-specific immune responses in hematological patients was
confirmed as a promising immunodiagnostic approach (Potenza
et al., 2013) amenable to combination with other diagnostic tools.
Finally, a stop codon in recipient TLR5 was also disclosed as an
important prognostic factor for the development of IA among
HSCT recipients (Grube et al., 2013), a finding warranting further
studies into the function of this receptor in antifungal immunity.
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Dectin-1 deficiency was also consistently reported to con-
tribute to susceptibility to IA (Cunha et al., 2010; Chai et al., 2011;
Sainz et al., 2012). The finding that by compromising the surface
expression and dectin-1-mediated cytokine production, the pres-
ence of the Y238X polymorphism in HSCT donors and recipients
displayed a cumulative effect toward risk for infection (Cunha
et al., 2010) emphasizes the contribution of non-hematopoietic
dectin-1 to antifungal immunity. In addition, although dam-
age perception is fundamental for resolution of fungal infection
(Cunha et al., 2012), genetic variants triggering hyperactive dan-
ger signaling, and presumably leading to uncontrolled inflamma-
tory responses to the fungus, were also recently found to increase
risk for IA (Cunha et al., 2011).
A number of positive associations between genetic variants in
cytokine and chemokine genes and vulnerability to IA has also
been reported (Sainz et al., 2007a,b, 2008, 2010; Mezger et al.,
2008; Carvalho et al., 2010). One recent example regards the
identification of polymorphisms in the genes encoding for IL-1b
and beta-defensin 1 (DEFB1) that, by affecting production of A.
fumigatus-induced proinflammatory cytokines by mononuclear
cells, influenced susceptibility to mold infection after solid organ
transplantation (Wojtowicz et al., 2014).
A number of unconventional strategies have been employed to
uncover additional candidate genes for susceptibility to IA (Zaas
et al., 2008; Durrant et al., 2011). For example, genetic mapping
analysis of survival data of infected mice allowed the identifica-
tion of plasminogen, a regulatory molecule with opsonic prop-
erties, as a fitting contestant for susceptibility (Zaas et al., 2008).
Consequently, a non-synonymous polymorphism in human plas-
minogen was found to increase risk for IA in HSCT recipi-
ents. Genetic and functional deficiency of other molecules with
opsonic activity—e.g.,mannose-binding lectin (MBL; Lambourne
et al., 2009) and PTX3 (Cunha et al., 2014a)—has also been
disclosed as a major determinant of susceptibility to IA, pointing
to a key contribution of innate humoral responses to antifun-
gal immunity. Indeed, a donor haplotype in PTX3 associated
FIGURE 1 | Schematic representation of a personalized medicine
approach to the management of IA. A prognostic score calculated
using information on host biomarkers and clinical factors is used to
determine the risk of IA associated to a given patient profile. The individual
aspects of the patient (and donor), including the genetic make-up and
downstream activated transcriptomic and proteomic or metabolomic
networks, as well as inherent clinical factors are directly considered to
guide treatment planning. Although the risk category is defined at initiation
of treatment (or before stem cell transplantation), it may be updated in the
course of treatment according to the clinical status of the patient (e.g.,
development of graft-versus-host-disease, prolonged neutropenia, etc.).
A number of host genetic variants in innate immunity genes (e.g., PTX3,
TLR4, dectin-1, MBL, and several cytokines) have been disclosed as
promising targets to use in patient-tailored strategies to optimize and target
the diagnostic workup, and the antifungal prophylaxis and therapy, thereby
improving patient outcome.
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with increased risk of IA in the correspondingHSCT recipient was
found to compromise PTX3 expression during the developmental
programming of neutrophils in the bone marrow, leading to a
defective antifungal capacity of newly reconstituted neutrophils
(Cunha et al., 2014a). Importantly, this association was recently
replicated in a cohort of solid organ transplant recipients (Woj-
towicz andBochud, 2015). The fact that exogenous administration
of PTX3 is able to revert the genetic defect (Cunha et al., 2014a)
further highlights the potential of PTX3-based immunotherapies
to treat (or prevent) IA (Carvalho et al., 2012a).
Decoding the Host-fungus Interaction into
Clinical Strategies
Early diagnosis is crucial to a favorable outcome of IA. However,
the existing diagnostic tools are often compromised by slowness,
invasiveness, lack of standardization and insufficient understating
of their kinetics (Hope et al., 2005). The introduction ofmolecular
and serological diagnostic techniques into clinical practice has
undoubtedly improved our capacity to diagnose IA. Nonetheless,
the broad applicability of both techniques is hampered by consid-
erable variability in performance. Given these technical barriers,
the search for tools to diagnose IA that are more efficient and reli-
able is an active field of research. One example was recently pro-
vided by a study demonstrating the usefulness of direct detection
of exogenous fungal metabolites in the breath to the identification
of the underlying microbial etiology of pneumonia (Koo et al.,
2014).
Although the interaction of the funguswith the immune system
is being exploited to project novel and improved fungal diag-
nostics, efforts have on the other hand been also devoted to the
implementation of clinical models aimed at the prediction of
infection in high-risk patients. In this regard, interpretation of
individual genomic, transcriptomic, proteomic or metabolomic
profiles associated with impaired antifungal immune responses
and their integration with clinical data is regarded as a promising
approach (Figure 1). Indeed, next-generation sequencing tech-
nologies now provide exciting possibilities to pin down essential
steps in host-fungus interaction at a level of complexity previ-
ously unanticipated. The first genome-wide association studies
(GWAS) exploring host susceptibility to IA are underway and
are expected to provide unbiased insights into the genetic defects
contributing to development of IA, thereby laying the foundation
for clinical trials aimed at the validation of medical interventions
based on individual genomics. These efforts are nonetheless cen-
tered on the fairly “static” role played by the genetic variants.
Physiological responses to fungal infection require the coordi-
nated regulation of gene expression, which may vary markedly
between individuals and influence phenotypes such as protein lev-
els, the cell morphology and function, and ultimately the immu-
nity to infection. Thus, genetic analysis of molecular traits such
as the gene expression represents a powerful approach enabling
insights into the human genomic landscape by generating expres-
sion maps useful for the functional interpretation of non-coding
variants likely to arise from ongoing genome-wide initiatives
(Fairfax and Knight, 2014).
Conclusions and Perspectives
The discovery of accurate and reliable genetic markers of suscep-
tibility may be a turning point toward innovative stratification
strategies based on genetic screening or immune profiling to pre-
dict risk and severity of disease, efficacy of antifungal prophylaxis
and therapy, and eventually contribute to the successful design of
antifungal vaccines. As shown for PTX3 deficiency (Cunha et al.,
2014a), targeting cell function (e.g., exogenous administration of
lacking or deficient factors) may prove an interesting approach
to be validated in the future. Indeed, engineering of T cell func-
tion to target carbohydrates was demonstrated as a potentially
exploitable strategy for the treatment of IA (Kumaresan et al.,
2014). Ultimately, approaches based on individual genomics (and
with influence on multiple functional transcriptomic, proteomic
and metabolomic networks) may warrant important clinical tools
allowing discrimination of patients that require enhanced surveil-
lance for fungal disease or alternative antifungal therapies.
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